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Introduction: In this study, we investigated the influence of smok-
ing on the postoperative prognosis in patients with non-small cell
lung cancer.
Methods: The subjects consisted of 770 patients who underwent a
resection of lung cancer in our department between 1994 and 2005.
We compared the clinico-pathological findings between the smoking
and never-smoking groups. The pack-year index (PYI) was used as
a smoking index.
Results: The smoking group consisted of 569 patients (74%), and
the never-smoking group consisted of 201 patients (26%). The
smokers were composed of 492 men and 77 women. Among the
adenocarcinoma patients, there were 293 (61%) smokers and 185
(39%) never-smokers. The patients with squamous cell carcinoma
included 204 (95%) smokers and 10 (5%) never-smokers. The
proportion of patients with stage IA disease was significantly higher
in the never-smokers than that of the smokers. The 5-year survival
rate after surgery was 66% in the never-smoking group; however,
the rates were 56% in patients with a PYI more than or equal to 20,
and 55% in those with PYI more than 20. Seventy-nine (13.9%)
patients in the smoking group and seven (3.5%) patients in the
never-smoking group died of other diseases, with a significant
difference (p  0.01). Of these patients, 44 (56%) and 13 (16%) in
the smoking group died of respiratory and cardiovascular disorders,
respectively. In our series, excluding those who died of other
diseases, there were no significant differences in the postoperative
prognosis.
Conclusions: In the smoking group, the prognosis was poorer than
that in the never-smoking group. The higher proportion of early
stage disease (stage IA) and female gender were major causes of the
better prognosis of the never-smokers. Nevertheless, the high pul-
monary/cardiovascular complication-related mortality was another
cause of the poor prognosis of the smokers with lung cancer.
Key Words: Non-small cell lung cancer, Smoking, Pulmonary
resection, Surgical outcome.
(J Thorac Oncol. 2008;3: 1127–1132)
Lung cancer is still the leading cause of cancer-relatedmortality in many industrialized countries.1,2 It becomes a
considerable public health problem, and reducing the death of
lung cancer remains an important issue. Smoking is well
known to be the main cause of lung cancer and therefore an
increase of lung cancer mortality is significantly associated
with the increase in the number of smokers.3 It was estimated
that 80 to 90% of lung cancer cases can be attributed to
smoking.4,5 Approximately one third of adults are known to
be smokers, and smoking rates are still increasing among the
female population. Intensive awareness campaigns to quit
smoking have greatly contributed to the prevention of lung
cancer as a primary prophylaxis.5–7 Moreover, smoking is
also strongly related to several pulmonary and cardiovascular
diseases such as chronic obstructive pulmonary disease,
asthma, hypertension, and ischemic heart disease.8 Because
passive smoke is also a well-known risk factor for such
respiratory diseases, including lung cancer, efforts to prohibit
both public smoking and workplace smoking have been
promoted over the past decade in several countries.
The effects of smoke on the respiratory system are
understood by two main mechanisms: inducing inflammation
and a mutagenic (carcinogenic) effect. Inflammation consists
of damage of the ciliated epithelia, increased mucus secre-
tion, and the accumulation of activated inflammatory cells in
the respiratory tract. Tobacco smoke contains more than 60
carcinogens, and among them the most harmful substances
are the polycyclic aromatic hydrocarbons and tobacco-spe-
cific nitrosamines.9,10 Therefore, tobacco smoke is an estab-
lished human carcinogen in not only lung cancer but also in
several other cancers such as cancer of larynx, oral cavity and
esophagus, and bladder, and it is associated with the concept
of field cancerization.11 Thirty percent of all cancers is
reported to be caused by smoking.12 Nevertheless, the influ-
ence of smoking on the prognosis of lung cancer remains to
be clarified. In the present study, we investigated the influ-
ence of smoking on the postoperative prognosis in patients
with non-small cell lung cancer (NSCLC).
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PATIENTS AND METHODS
The subjects consisted of 770 patients who underwent
resection of primary NSCLC in our department between 1994
and 2005. We compared the clinico-pathological findings
between the smoking and never-smoking groups. The pa-
tients’ records including the clinical data, preoperative exam-
ination results, details of surgical operation, histopathological
findings, and tumor, node, metastasis staging were also re-
viewed. The history of cigarette smoking was thoroughly
evaluated according to the description given in the patient’s
medical records on admission. The pack-year index (PYI)
was used as a smoking index. The PYI was defined as the
number of cigarette packs (20 cigarettes per pack) consumed
a day multiplied by years. The patients were classified to
three subgroups according to the PYI as never-smoker, less
than 20 (PYI 20), and more than 20 (PYI 20). Never-
smokers were defined as having less than 20 cigarettes in a
lifetime. The calculation of PYI for smokers included both
current smoking and former smoking.
The preoperative assessments included chest roentgen-
ography, computed tomography of the chest, and upper ab-
domen, magnetic resonance imaging of brain, bronchoscopy,
and bone scintigraphy. All resected specimens including the
primary tumor and the systematically dissected hilar and
mediastinal lymph nodes were examined for tumor histology
and the extent of lymph node metastases. The histopatholog-
ical findings were classified according to the World Health
Organization criteria and the Union Internationale Contra le
Cancer tumor, node, metastasis staging system were em-
ployed.13,14 The reasons for classifying 35 patients as stage
IV included pulmonary metastasis in 17, bone metastasis in 7,
axillay lymph node metastasis in 4, adrenal metastasis in 3,
liver metastasis in 2, brain metastasis in 1, and metastasis of
the kidney in 1 patient. The pulmonary metastasis, axillary
lymph node metastasis, and adrenal metastasis were also
resected either concurrently or sequentially. Bone metas-
tasis was treated using radiotherapy, and brain metastasis
was also treated by gamma knife therapy.
Follow-up information was obtained from all patients
through office visits or telephone interviews with either the
patient, a relative, or their primary physicians. The mean
observation time was 3.3 years. The survival curve was
calculated by the Kaplan-Meier method, and compared by
using the log-rank test for univariate analysis. The prognostic
factors were analyzed by a multivariate analysis using Cox’s
proportional hazard model after adjusting for potential con-
founding factors. Categorical variables were compared by
Fisher’s exact test for proportion. The differences were con-
sidered to be significant if the p value was less than 0.05. The
Statview V software program (Abacus Concept, Berkeley,
CA) was used for all statistical analyses.
RESULTS
The smoking group consisted of 569 (73.9%) patients,
and the never-smoking group consisted of 201 (26.1%) pa-
tients (Table 1). Concerning gender, the 569 patients con-
sisted of 492 (86.5%) men and 77 (13.5%) women. The
never-smoking group was composed of 33 (16.4%) men and
168 (83.6%) women. The proportion of women in the never-
smokers was significantly higher than that of men. The
proportion of adenocarcinoma was significantly higher in the
never-smokers than the smokers. In the smokers with PYI
more than 20, pathological stage IA disease were less fre-
quent than that in the never-smoking group (Table 1). Among
adenocarcinoma patients, there were 293 (61.3%) smokers
and 185 (38.7%) never-smokers. The proportion of patients
with stage IA adenocarcinoma was significantly higher in
never-smokers than that in the smokers with PYI more than
20 (p  0.01). There was no difference in the presence or
absence of symptoms between smokers and never-smokers.
The patients with squamous cell carcinoma consisted of 204
(95.3%) smokers and 10 (4.7%) never-smokers.
The 5-year survival rate after surgery was 66.8% in the
never-smokers. The rates were 56.2% in the smokers with
PYI less than or equal to 20 and 55.1% in those with PYI
more than 20 (Figure 1A). The prognosis was significantly
poorer in the smokers with PYI more than 20 than that of the
never-smokers (p  0.001). The 5-year survival rates in
patients at stage I were 83.2%, 77.8%, and 69.9% in the
never-smokers, smokers with PYI of 20 or less, and those
with PYI more than 20, respectively (Figure 1B). In patients
at stage I, the prognosis was also significantly poorer in the
smokers with PYI more than 20 than that of the never-
smokers (p  0.007). In patients at stage II and III, no
significant differences were observed among the three groups
(Figures 1C, D). In the patients with adenocarcinoma, the
overall survival was significantly lower in the smoking group
(smokers with PYI 20; 59.1%, PYI 20; 59.7%) than that
of the never-smokers (70.3%) (p  0.022) (Figure 2). In a
TABLE 1. Characteristics of Non-small Cell Lung Cancer
Patients According to Smoking History
Characteristics
Smoker
(PYI >20)
(n  492)
Number of
Patients (%)
Smoker
(PYI <20)
(n  77)
Number of
Patients (%)
Never Smoker
(n  201)
Number of
Patients (%)
Male 444 (90.2) 48 (62.3) 33 (16.4)a
Female 48 (9.8) 29 (37.7) 168 (83.6)
Histology
Adenocarcinoma 232 (47.2) 59 (76.6) 185 (92.0)b
Squamous cell ca. 193 (39.2) 11 (14.3) 10 (5.0)
Large cell ca. 36 (7.3) 1 (1.3) 1 (0.5)
Others 31 (6.3) 6 (7.8) 5 (2.5)
Pathological stage
IA 138 (28.0) 34 (44.2) 99 (49.3)c
IB 102 (20.7) 11 (14.3) 35 (17.4)
II 77 (15.7) 7 (9.1) 14 (7.0)
IIIA 108 (22.0) 9 (11.7) 19 (9.5)
IIIB 45 (9.1) 13 (16.9) 24 (11.9)
IV 22 (4.5) 3 (3.9) 10 (5.0)
a The proportion of never smokers was significantly lower in men than in women
(p  0.01).
b The incidence of adenocarcinoma in the never smoker was significantly higher
than that in the other smoker groups (both in PYI 20 and PYI 20) (p  0.01).
c The proportion of stage IA disease in never smokers was significantly higher than
that in the smokers with PYI 20 (p  0.01).
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multivariate analysis using variables such as smoking, sex,
age, pathological stage, T factor, and N factor as significant
prognostic factors, smoking was not a significant prognostic
factor independent of the other factors (p  0.871) (Table 2).
Because the smoking status was suggested to be a prognostic
factor for stage I, a multivariate analysis was therefore also
performed. Because smoking was more popular for men than
women, and squamous cell carcinoma was more frequently
observed than adenocarcinoma, both the sex and histological
type were thus included in the analysis. Although being a
never-smoker was found to be a significantly better prognos-
tic factor based on a univariate analysis (p  0.007), the
hazard ratio of never-smokers in a multivariate analysis was
0.893 (p 0.758), and therefore smoking was not determined
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FIGURE 1. Overall survival curves of patients according to smoking history. A, Overall survival curves of all patients ac-
cording to smoking history. The 5-year survival rates were 66.8%, 56.2%, and 55.1% in never-smokers, smokers with PYI
20, and smokes with PYI 20, respectively. The prognosis was significantly poorer in the smokers with PYI 20 than
that of the never-smokers (p  0.001). B, The 5-year survival rates in patients at stage I were 83.2%, 77.8%, and 69.9%
in the never-smokers, smokers with PYI 20, and smokers with PYI 20, respectively. In patients at stage I, the progno-
sis was also significantly poorer in the smokers with PYI 20 than that of the never-smokers (p  0.007). C, The overall
survival in the patients at stage II. There was no significant difference among the three groups (never-smoker; 45.0%,
smokers with PYI 20; 42.9%, smokers with PYI 20; 53.9%). D, The overall survival in the patients at stage III. The 5-year
survival rates were 42.0% in the never-smokers, 17.8% in smokers with PYI 20, and 35.5% in smokers with PYI 20.
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FIGURE 2. Overall survival curves of patients with adeno-
carcinoma according to smoking history. In the patients
with adenocarcinoma, the 5-year survival rates were
70.3%, 59.1%, and 59.7% in never-smokers, smokers
with PYI 20, and smokers with PYI 20, respectively.
The never-smoker had a significantly more favorable prog-
nosis than smokers with PYI 20 (p  0.01).
TABLE 2. Multivariate Cox Proportional Hazard Analysis of
the Overall Survival in All Patients
Factors
Relative
Risk
95%
Confidence
Interval p
Women vs. men 0.706 0.483–1.032 0.070
Tumor size (T1 vs. T2–4) 0.412 0.301–0.563 0.001
Nodal status (N0 vs. N1–3) 0.478 0.369–0.620 0.001
Histology (adenocarcinoma
vs. others)
0.956 0.722–1.266 0.752
Age (75 vs. 75) 0.716 0.537–0.954 0.022
Smoking status (never smoker
vs. former and current
smoker)
0.967 0.688–1.322 0.871
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to be a significant independent prognostic factor in patients at
stage I (Table 3).
Seventy-nine (13.9%) patients in the smoking group
(smokers with PYI 20 and PYI 20) and seven (3.5%)
patients in the never-smoking group died of other than lung
cancer, thus indicating a significant difference in mortality
rate caused by other diseases (p  0.01) (Table 4). Of these
patients, 41 (8.3%) of the smokers with a PYI more than 20
and two (1.0%) in the never-smoking group died of respira-
tory disease, thus indicating a significant difference (p 
0.01). Eleven (3.8%) patients in the smoking group and 1
(0.5%) in the never-smoking group died because of cardio-
vascular disorders. Fourteen patients in the smoking group
died of other cancers (second primary lung cancer in five,
esophageal cancer in two, laryngeal cancer in two, hepatoma
in two, gastric cancer in one, colon cancer in one, and
pancreatic cancer in one). On the other hand, three patients
among 201 never-smokers died of two gastric cancers and
one colon cancer, respectively. The death from primary
cancer other than lung cancer tended to be more frequent
(2.6%) in the smokers with PYI more than 20 than that
(1.5%) of the never-smoker. Of our series, excluding those
who died of other than lung cancer, the 5-year survival
rates were 70.2% in the never-smoking group, 67.3% in
the smokers with a PYI less than or equal to 20, and 66.5%
in those with a PYI more than 20. Nevertheless, no
significant differences were observed among cancer-spe-
cific survival (Figure 3).
DISCUSSION
Smoking is an apparent risk factor for the development
of lung cancer.15,16 Compared with never-smokers, heavy
smokers are 10 to 20 times more likely to develop lung
cancer.17 Smoking is also responsible not only for lung cancer
but also for such aero-digestive tract tumors as the larynx,
oral cavity, and esophagus.9–11 Slaughter et al.11 first pro-
posed the concept of “field cancerization” based on observa-
tions of the occurrence of multiple primary tumors. Tobacco
smoking induces somatic mutations with various DNA dam-
age such as mutation of p53, and the normal epithelium can
be “preconditioned” by carcinogen exposure contained in
smoke.18 Cigarette smoke contains about 4000 chemical
agents, including over 60 carcinogens such as polycyclic
aromatic hydrocarbons, N-nitrosamines, aromatic amines,
heterocyclic aromatic amines, and aldehydes.10 Smoking is
well known to have a strong association with the incidence of
squamous cell carcinoma and small cell carcinoma as com-
pared with adenocarcinoma.19 Nevertheless, smoking also
reported to contribute to the development of multiple primary
lung adenocarcinomas, especially in patients with preexisting
atypical adenomatous hyperplasia.20
Smoking not only causes lung cancer but it also might
negatively affect the prognosis of patients with lung cancer. It
is known that smoking affects the systemic immune response
and reduces the proliferative activity of the helper T cells and
B cells.21 Smoking contributes to an increase in the white
blood cell count and a decline in the circulating natural killer
(NK) cell count.22 The host immune defense mechanisms
might play an important role in eliminating cancer cells and
controlling tumor growth and metastases formation. Several
investigators also reported that smokers had lower levels of
NK-cell activity than non-smokers and smoking impaired the
systemic NK cell-dependent tumor immune surveillance.23,24
Moreover, smoking has been reported to reduce local airway
immunity and that the alveolar macrophages of smokers
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FIGURE 3. Cancer-specific survival curves of the patients
according to smoking history. With the exception of death
caused by unrelated disease, the 5-year survival rates were
70.2%, 67.3%, and 69.6% in never-smokers, smokers with
PYI 20, and smokers with PYI 20, respectively. There was
no significant difference.
TABLE 3. Multivariate Cox Proportional Hazard Analysis of
the Overall Survival in Patients at Stage I
Factors
Relative
Risk
95%
Confidence
Interval p
Women vs. men 0.589 0.255–0.638 0.122
Tumor size (T1 vs. T2) 0.403 0.301–0.563 0.001
Histology (adenocarcinoma
vs. others)
0.997 0.610–1.630 0.990
Age (75 vs. 75) 0.574 0.364–0.907 0.017
Smoking status (never smoker
vs. former and current
smoker)
0.893 0.434–1.837 0.758
TABLE 4. Causes of Death Unrelated to Lung Cancer
Cause of Death
Smoker
(PYI >20)
(n  492)
Smoker
(PYI <20)
(n  77)
Number of
Patients (%)
Never Smoker
(n  201)
Number of
Patients (%)
Pulmonary disease 41 (8.3)a 3 (3.9) 2 (1.0)
Cardiac and cerebrovascular
disease
8 (1.6) 3 (3.9) 1 (0.5)
Other cancer 13 (2.6) 1 (1.3) 3 (1.5)
Others 9 (1.9) 1 (1.3) 1 (0.5)
Total 71 (14.4) 8 (10.4) 7 (3.5)
a The incidence of death due to pulmonary disease was significantly higher in the
smokers with PI 20 than those in never smokers (p  0.01).
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suppressed NK cell activity by producing prostaglandins and
oxygen radicals.25 Smoking may induce damages of numer-
ous alveolar macrophage functions, and it inhibited macro-
phage accumulation and markedly reduced phagocytic and
microbicidal activity of the alveolar macrophage.25
It is considered that smoking may induce resistance to
chemotherapeutic agents of lung cancer by altering metabo-
lism for such drugs by induction of cytochrome P450 (CYP).4
The nicotinic acetylcholine receptors in bronchial and vascu-
lar endothelial cells respond to acetylcholine, nicotine, or
some nitrosoamines and modulate cell proliferation through
the calcium-dependent pathways.26 Smoking induces muta-
tions through the formation of DNA-adducts in the bronchial
and alveolar epithelium and contributes to the development of
lung cancer. The expression of CYP and arylhydrocarbon
receptor in the bronchial epithelium was increased in heavy
smokers with NSCLC, and CYP positivity showed a close
correlation with a poor survival of lung cancer patients.27
Tsao et al.28 reported that never-smokers were found to have
a better outcome over smokers when treated with chemother-
apy, although continued smoking during the chemotherapy
did not affect on survival. Another retrospective report dem-
onstrated that former and never-smokers had also better
survival rates than current smokers.29 Regarding the smoking
status on radiation therapy for NSCLC, it was reported that
current smokers with stage I and II disease may have a poorer
prognosis than the non-smoker after radiation therapy.30
Bryant et al.31 reported that never-smokers who de-
velop NSCLC are more likely to be young and women, and
that never-smokers show a significantly better survival than
smokers. In the present study, the proportion of patients
with stage IA was also significantly higher in never-
smokers than that in smokers. Moreover, proportion of
women in the never-smokers (83.5%) was significantly
higher than in the smokers (13.5%). These might be major
causes for the favorable prognosis of the never-smokers.
Nevertheless, when death from other than lung cancer was
excluded, smoking was not found to be a prognostic factor.
Smoking is also responsible for several pulmonary and
cardiovascular diseases such as chronic obstructive pulmo-
nary disease, asthma, hypertension, atherosclerosis, and
ischemic heart disease, all of which have a significant
systemic impact for the patient’s condition.8 The preva-
lence of pulmonary/cardiovascular complication-related
mortality after surgery was significantly higher in the
smokers than the never-smokers (Table 4).
Baliunas et al.32 reported that cigarette smoking is one
of the most important risk factors for the burden of various
diseases and is a major contributor to mortality including
malignant neoplasms, cardiovascular diseases, and respira-
tory diseases. These findings suggest that the unfavorable
prognosis of smokers might not be because of the biological
behavior of lung cancer. The studies about influences of
smoking on genetic alteration and damage of lung tissue, and
suppression of immune surveillance should be necessary for
further understanding of the biological behavior of lung
cancer in smokers.
We concluded that the prognosis of postoperative pa-
tients with lung cancer was poorer in the smoking group than
that in the never-smoking group. It was thus considered that
higher proportions of early stage disease (stage IA) and
female gender were a major cause of the better prognosis of
the never-smoker. Nevertheless, the high pulmonary/cardio-
vascular complication-related mortality was another cause of
the poor prognosis of the smokers with lung cancer. There-
fore, the harmful effects of smoking against complicating
benign diseases, and carcinogenesis of other aero-digestive
tract tumors were thus found to have a substantial influence
on the postoperative prognosis of primary NSCLC. Further
prospective studies and better documentation of smoking
history and passive smoking are therefore required to better
characterize the effect of smoking on the prognosis of surgi-
cal treatment.
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